Jack Meehan

Stock Analyst at Barclays

(3.05)
# 1,265
Out of 5,143 analysts
137
Total ratings
69.51%
Success rate
21.33%
Average return

Stocks Rated by Jack Meehan

Labcorp Holdings
Oct 2, 2025
Maintains: Equal-Weight
Price Target: $275$290
Current: $269.97
Upside: +7.42%
Agilent Technologies
Feb 28, 2024
Maintains: Underweight
Price Target: $120$125
Current: $138.63
Upside: -9.83%
Waters
Aug 3, 2023
Maintains: Equal-Weight
Price Target: $275$288
Current: $400.42
Upside: -28.08%
Avantor
Mar 3, 2021
Initiates: Overweight
Price Target: $33
Current: $12.24
Upside: +169.61%
Illumina
Mar 3, 2021
Initiates: Underweight
Price Target: $325
Current: $153.95
Upside: +111.11%
InMode
Aug 17, 2020
Maintains: Overweight
Price Target: $18$19
Current: $14.08
Upside: +34.94%
Quest Diagnostics
Apr 23, 2020
Maintains: Equal-Weight
Price Target: $93$99
Current: $182.16
Upside: -45.65%
ICON Public Limited Company
Apr 23, 2020
Maintains: Overweight
Price Target: $170$180
Current: $186.74
Upside: -3.61%
Myriad Genetics
Mar 26, 2020
Maintains: Underweight
Price Target: $14$10
Current: $6.06
Upside: +65.02%
IQVIA Holdings
Mar 26, 2020
Maintains: Overweight
Price Target: $192$166
Current: $239.05
Upside: -30.56%
Maintains: Equal-Weight
Price Target: $51$43
Current: $75.11
Upside: -42.75%
Maintains: Equal-Weight
Price Target: $170$154
Current: $224.03
Upside: -31.26%
Maintains: Overweight
Price Target: $435$430
Current: $305.22
Upside: +40.88%
Maintains: Overweight
Price Target: $435$430
Current: $310.40
Upside: +38.53%
Downgrades: Equal-Weight
Price Target: n/a
Current: $30.56
Upside: -
Upgrades: Overweight
Price Target: $52$48
Current: $52.11
Upside: -7.89%
Upgrades: Equal-Weight
Price Target: $720$680
Current: $1,438.11
Upside: -52.72%
Maintains: Underweight
Price Target: $28$30
Current: $78.62
Upside: -61.84%
Maintains: Overweight
Price Target: $295$300
Current: $639.45
Upside: -53.08%
Initiates: Equal-Weight
Price Target: $40
Current: $0.94
Upside: +4,172.36%